Clinical trial · Interventional
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
NCT00384553CI-TRIAL-00000467unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkins's Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous stem cell transplantation | Drug | — | UNRESOLVED |
| DHAP | Drug | — | UNRESOLVED |
| Rituximab | Drug | Rituximab | ALIAS |
| TEC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Toxicity
Secondary outcomes (4)
- measure
- remission rate
- measure
- remission duration
- measure
- overall survival
- measure
- relapse free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV * pretreatment with systemic therapy * 18-65 years of age * Performance status:ECOG 0-2 * Granulocyte count \>1.5/µm3, Platelet count \>100/µm3 * Creatinine -Clearance ≥ 1 ml/sec * GPT/GOT ≤ 1.5 x normal (except tumour related) * Bilirubine \< 22 µmol/l * no participation in another study 3 month before and during this study * informed consent Exclusion Criteria: * Second neoplasia in history or existing except basalioma or squamous epithelium carcinoma of the skin or removed cervical intraepithelial neoplasia * CNS- involvement by lymphoma * respiratory Partial- or global insufficiency * cardiac insufficiency (NYHA-Stage 3-4, EF \< 30 %) * severe neurological or psychiatric disease * pregnancy * HIV positivity ,active virus hepatitis, bacterial infection * No follow up procedures ensured
References
Publications (0)
Data not yet available
No reference posted for this study.